

31st July 2013

ASX ANNOUNCEMENT

APPENDIX 4C - QUARTERLY CASH FLOW

Analytica Limited (the Company) presents its Appendix 4C for the quarter ended 30th June 2013.

Cash Position

The Company held cash reserves at the end of the period of \$349,000.

Research and development expenditure (\$154k), staff costs (\$149k), marketing expenses (\$54k) accounted for the bulk of the operating cash flows for the quarter. A receipt of \$498,000 for Research and Development taxation incentive was received this quarter.

The Company continues to have a line of credit of \$400,000 to ensure adequate funding of the Company.

The company anticipates lodging the 2013 Research and Development taxation incentive claim this quarter and receiving approximately \$530,000.

Brazil

Negotiations continue in order to finalise a distribution agreement for the AutoStart® Infusion System in Brazil.

Taiwan

During the quarter a distribution agreement was signed with Taiwan Allied Dragon Inc (TAD). TAD Chairman Mr Cotch Liao, indicated that Taiwan has a market roughly the size of Australia, with a good health system backed by the Government and Insurance companies. The regulatory process for permitting the AutoStart Infusion System to be used in Taiwan is underway.

PeriCoach® System.

The PeriCoach system has been developed in association with leading specialist physiotherapists, midwives and urologists, to address female stress urinary incontinence, most commonly caused by a weak pelvic floor. This is estimated to effect 4.2 million Australians and incur a personal cost of 191.2 million on incontinence products and a total financial cost to Australia of \$42.9 billion.

Performing exercises to engage and train the pelvic floor muscle group is one of the most common ways to treat and even reverse stress urinary incontinence. Correct technique is vital but difficult to achieve. The PeriCoach system gives a complete picture of what's happening when performing exercises, is first to utilise blue tooth to provide a compact, discreet and portable solution backed by powerful data analysis and clinician support.

Shareholders should have received a newsletter providing an update on the development of this exciting product. The PeriCoach has been in development for 4 years and is on schedule to be released before Christmas this year.

To fund the completion of this project the company expects to raise further capital this quarter by means of a share purchase plan.

3 Investor presentation sessions will be held in the evenings starting at 6pm at the following venues:

- **Brisbane - Monday 12th Aug**
First Fleet Room, Level 1, Christie Conference Centre, 320 Adelaide Street, Brisbane, QLD
- **Sydney - Tuesday 13th Aug**
Qing Room, Level 2, Christie Conference Centre, 3 Spring Street, Sydney NSW.
- **Sunshine Coast - Wednesday 14th Aug**
Twin Waters Resort, Ocean Drive, Twin Waters, Sunshine Coast, QLD.

Analytica aims to use these sessions to keep our loyal shareholders informed on development with the AutoStart Infusion Systems and to answer your questions regarding our newest product – the PeriCoach System.

To attend, please register by sending an email to events@analyticamedical.com by Friday 9th Aug with your name and contact details, and nominating which session you wish to attend.

Please also take the opportunity to subscribe to the company mailing list by visiting on the company website: www.analyticamedical.com

Dr Michael Monsour

Chairman, Board of Directors

Analytica Limited (ASX:ALT) is an Australian company dedicated to the design, development and supply of a range of Class I and IIa medical devices.



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

30 June 2013

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (12 months) \$A'000
1.1	Receipts from customers		
1.2	Payments for		
	(a) staff costs	(149)	(578)
	(b) advertising and marketing	(54)	(135)
	(c) research and development	(154)	(561)
	(d) leased assets	-	-
	(e) other working capital	(118)	(300)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	5	33
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other-		
	(a) Net sales income	-	-
	(b) R & D Tax Concession	498	656
	(c) Royalty Income	-	10
Net operating cash flows		28	(875)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	28	(875)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(1)	(6)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (purchase of Convertible Notes)	-	-
Net investing cash flows	(1)-	(6)
1.14 Total operating and investing cash flows	27	(881)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares	-	5
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	12
1.18 Repayment of borrowings:	-	-
1.19 Dividends paid	-	-
1.20 Other Creditors (costs of fund raising)	-	-
Net financing cash flows	-	17
Net increase (decrease) in cash held	27	(864)
1.21 Cash at beginning of quarter/year to date	322	1213
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	349	349

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	48
1.25	Aggregate amount of loans to the parties included in item 1.11	13
1.26	Explanation necessary for an understanding of the transactions	
	Payment of director's fees and compulsory superannuation.	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	400	-
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	349	322
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		349	322

Acquisitions and disposals of business entities

		Acquisitions	Disposals
5.1	Name of entity	N/A	N/A
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets		
5.5	Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: Original signed

Date: 31 July 2013

Print name: Ross Mangelsdorf

+ See chapter 19 for defined terms.